Profile data is unavailable for this security.
About the company
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
- Revenue in USD (TTM)0.00
- Net income in USD-119.24m
- Incorporated2019
- Employees65.00
- LocationBioatla Inc11085 Torreyana RoadSAN DIEGO 92121United StatesUSA
- Phone+1 (858) 558-0708
- Fax+1 (858) 558-0701
- Websitehttps://www.bioatla.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aileron Therapeutics Inc | 0.00 | -18.07m | 69.09m | 15.00 | -- | 1.20 | -- | -- | -3.19 | -3.19 | 0.00 | 5.42 | 0.00 | -- | -- | 0.00 | -31.05 | -65.99 | -33.17 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
Rallybio Corp | 0.00 | -76.28m | 69.22m | 43.00 | -- | 0.7083 | -- | -- | -1.88 | -1.88 | 0.00 | 2.36 | 0.00 | -- | -- | 0.00 | -58.30 | -- | -62.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
Instil Bio Inc | 0.00 | -123.32m | 69.53m | 49.00 | -- | 0.3378 | -- | -- | -18.96 | -18.96 | 0.00 | 31.65 | 0.00 | -- | -- | 0.00 | -33.63 | -- | -35.47 | -- | -- | -- | -- | -- | -- | -- | 0.2841 | -- | -- | -- | 30.06 | -- | -- | -- |
Checkpoint Therapeutics Inc | 68.00k | -52.32m | 70.02m | 23.00 | -- | -- | -- | 1,029.64 | -2.37 | -2.37 | 0.0028 | -0.2872 | 0.0076 | -- | -- | 2,956.52 | -585.51 | -142.43 | -- | -342.79 | -- | -- | -76,938.23 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
vTv Therapeutics Inc | 1.00m | -20.62m | 70.23m | 16.00 | -- | 3.38 | -- | 70.23 | -8.76 | -8.76 | 0.383 | 6.91 | 0.0241 | -- | 2.04 | 62,500.00 | -63.15 | -111.84 | -128.59 | -- | -- | -- | -2,621.10 | -680.94 | -- | -- | 0.00 | -- | -100.00 | -- | -5.67 | -- | -- | -- |
Passage Bio Inc | 0.00 | -84.44m | 70.27m | 58.00 | -- | 0.6697 | -- | -- | -1.53 | -1.53 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -47.73 | -48.56 | -52.17 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
Provectus Biopharmaceuticals Inc | 590.75k | -2.78m | 71.32m | 4.00 | -- | -- | -- | 120.73 | -0.0066 | -0.0066 | 0.0014 | -0.0178 | 0.4221 | -- | 1,358.05 | 147,687.50 | -198.50 | -276.33 | -- | -- | -- | -- | -470.31 | -1,667.76 | -- | -10.24 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
Benitec Biopharma Inc | 7.00k | -21.69m | 71.66m | 18.00 | -- | 1.81 | -- | 10,237.32 | -9.87 | -9.87 | 0.0031 | 4.22 | 0.0006 | -- | 0.1284 | 388.89 | -186.85 | -83.43 | -260.89 | -98.77 | 1,542.86 | 96.86 | -309,885.70 | -468.04 | -- | -307.03 | 0.00 | -- | 2.74 | -53.84 | -7.44 | -- | -56.51 | -- |
Alpha Teknova Inc | 36.85m | -36.06m | 71.85m | 210.00 | -- | 0.8617 | -- | 1.95 | -1.05 | -1.05 | 1.05 | 2.04 | 0.2815 | 2.29 | 7.89 | 175,490.50 | -27.54 | -- | -29.30 | -- | 27.36 | -- | -97.85 | -- | 3.92 | -28.23 | 0.1365 | -- | -11.43 | -- | 22.52 | -- | -- | -- |
Bioatla Inc | 0.00 | -119.24m | 72.66m | 65.00 | -- | 1.46 | -- | -- | -2.49 | -2.49 | 0.00 | 1.03 | 0.00 | -- | -- | 0.00 | -81.18 | -48.72 | -96.07 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
Annovis Bio Inc | 0.00 | -47.53m | 73.17m | 6.00 | -- | -- | -- | -- | -5.04 | -5.04 | 0.00 | -0.3046 | 0.00 | -- | -- | 0.00 | -284.97 | -106.31 | -411.92 | -124.71 | -- | -- | -- | -- | -- | -9.20 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
Aclaris Therapeutics Inc | 31.12m | -77.26m | 73.40m | 91.00 | -- | 0.5168 | -- | 2.36 | -1.09 | -1.09 | 0.4392 | 1.99 | 0.1541 | -- | 58.77 | 341,967.00 | -38.27 | -47.29 | -42.29 | -53.87 | 41.99 | 44.00 | -248.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
Tempest Therapeutics Inc | 0.00 | -29.76m | 73.76m | 17.00 | -- | 3.58 | -- | -- | -1.76 | -1.76 | 0.00 | 0.9287 | 0.00 | -- | -- | 0.00 | -72.84 | -57.10 | -93.72 | -71.20 | -- | -- | -- | -- | -- | -141.39 | 0.3394 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
MDxHealth SA - ADR | 75.33m | -39.90m | 75.04m | 300.00 | -- | -- | -- | 0.9962 | -1.14 | -1.14 | 0.8428 | -0.0357 | 0.5528 | 11.06 | 6.95 | 251,090.00 | -29.28 | -51.62 | -33.98 | -64.72 | 62.76 | 50.88 | -52.97 | -117.64 | 1.53 | -1.54 | 1.02 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
Bakhu Holdings Corp | 0.00 | -1.92m | 75.33m | 2.00 | -- | -- | -- | -- | -0.0064 | -0.0064 | 0.00 | -0.0325 | 0.00 | -- | -- | 0.00 | -281.75 | -4,391.82 | -- | -- | -- | -- | -- | -- | -- | -8.39 | -- | -- | -- | -- | 33.37 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Soleus Capital Management LP (Investment Management)as of 12 Apr 2024 | 3.89m | 8.10% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.53m | 5.27% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.06m | 4.29% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.90m | 3.94% |
Tang Capital Management LLCas of 31 Mar 2024 | 1.47m | 3.07% |
Cormorant Asset Management LPas of 31 Mar 2024 | 1.17m | 2.43% |
Renaissance Technologies LLCas of 31 Mar 2024 | 996.30k | 2.07% |
Geode Capital Management LLCas of 31 Mar 2024 | 922.94k | 1.92% |
Millennium Management LLCas of 31 Mar 2024 | 873.65k | 1.82% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 791.28k | 1.65% |